MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1126/scitranslmed.ade3901

Медицинская библиотека · Science translational medicine · 2023

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.

Dold Christina, Marsay Leanne, Wang Nelson, Silva-Reyes Laura, Clutterbuck Elizabeth, Paterson Gavin K, Sharkey Kelsey, Wyllie David, Beernink Peter T, Hill Adrian V, Pollard Andrew J, Rollier Christine S

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Adenoviral-vectored vaccines are licensed for prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ebola virus, but, for bacterial proteins, expression in a eukaryotic cell may affect the antigen's localization and conformation or lead to unwanted glycosylation. Here, we investigated the potential use of an adenoviral-vectored vaccine platform for capsular group B meningococcus (MenB). Vector-based candidate vaccines expressing MenB antigen factor H binding protein (fHbp) were generated, and immunogenicity was assessed in mouse models, including the functional antibody response by serum bactericidal assay (SBA) using human complement. All adenovirus-based vaccine candidates induced high antigen-specific antibody and T cell responses. A single dose induced functional serum bactericidal responses with titers superior or equal to those induced by two doses of protein-based comparators, as well as longer persistence and a similar breadth. The fHbp transgene was further optimized for human use by incorporating a mutation abrogating binding to the human complement inhibitor factor H. The resulting vaccine candidate induced high and persistent SBA responses in transgenic mice expressing human factor H. The optimized transgene was inserted into the clinically relevant ChAdOx1 backbone, and this vaccine has now progressed to clinical development. The results of this preclinical vaccine development study underline the potential of vaccines based on genetic material to induce functional antibody responses against bacterial outer membrane proteins.

Для цитирования: Dold Christina, Marsay Leanne, Wang Nelson, Silva-Reyes Laura, Clutterbuck Elizabeth, Paterson Gavin K, Sharkey Kelsey, Wyllie David, Beernink Peter T, Hill Adrian V, Pollard Andrew J, Rollier Christine S. An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.. Science translational medicine. 2023. DOI: 10.1126/scitranslmed.ade3901.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.